Humar Matjaz, Andriopoulos Nikolaos, Pischke Soeren E, Loop Torsten, Schmidt Rene, Hoetzel Alexander, Roesslein Martin, Pahl Heike L, Geiger Klaus K, Pannen Benedikt H J
Anaesthesiologische Universitätsklinik, Hugstetterstrasse 55, D-79106 Freiburg, Germany.
J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
Barbiturates are known to suppress protective immunity, and their therapeutic use is associated with nosocomial infections. Although barbiturates inhibit T cell proliferation, differentiation, and cytokine synthesis, only thiobarbiturates markedly reduce the activation of immune regulatory transcription factors such as nuclear factor-kappaB and nuclear factor of activated T cells. In this study, we investigated barbiturate-mediated effects on the regulation of the transcription factor activator protein 1 (AP-1) in primary T lymphocytes. We show that both thiobarbiturates and their oxy-analogs inhibit AP-1-dependent gene expression and AP-1 complex formation at clinically relevant doses. Furthermore, mitogen-activated protein (MAP) kinase activity, which transcriptionally and posttranslationally regulates AP-1 complex formation, is suppressed by most barbiturates. CD3/CD28- or phorbol 12-myristate 13-acetate (PMA)/ionomycin-induced p38 and extracellular signal-regulated kinase 1/2 phosphorylation or c-jun NH2-terminal kinase (JNK) 1/2 kinase activity was significantly diminished by pentobarbital, thiamylal, secobarbital, or methohexital treatment. These barbiturates also inhibited the initiators of the MAP kinase cascade, the small G proteins ras and rac-1, and prevented binding to their partners raf-1 and PAK, respectively. Thiopental, unlike the other barbiturates, only reduced ras and JNK activity upon direct CD3/CD28 receptor engagement. Contrarily, upon PMA/ionomycin stimulation, thiopental blocked AP-1-dependent gene expression independently of the small G protein ras and MAP kinases, thus suggesting an additional, unknown mechanism of AP-1 regulation. In conclusion, our results contribute to the explanation of a clinically manifested immune suppression in barbiturate-treated patients and support the idea of a MAP kinase-independent regulation of AP-1 by PKC and calcium in human T cells.
已知巴比妥类药物会抑制保护性免疫,其治疗用途与医院感染有关。尽管巴比妥类药物会抑制T细胞增殖、分化和细胞因子合成,但只有硫代巴比妥类药物能显著降低免疫调节转录因子如核因子-κB和活化T细胞核因子的活性。在本研究中,我们调查了巴比妥类药物对原代T淋巴细胞中转录因子激活蛋白1(AP-1)调控的影响。我们发现,硫代巴比妥类药物及其氧类似物在临床相关剂量下均能抑制AP-1依赖的基因表达和AP-1复合物形成。此外,大多数巴比妥类药物会抑制有丝分裂原激活蛋白(MAP)激酶活性,该活性在转录和翻译后水平调节AP-1复合物形成。戊巴比妥、硫喷妥钠、司可巴比妥或美索比妥处理可显著降低CD3/CD28或佛波酯12-肉豆蔻酸酯13-乙酸酯(PMA)/离子霉素诱导的p38和细胞外信号调节激酶1/2磷酸化或c-jun氨基末端激酶(JNK)1/2激酶活性。这些巴比妥类药物还抑制了MAP激酶级联反应的启动子小G蛋白ras和rac-1,并分别阻止它们与伴侣raf-1和PAK结合。与其他巴比妥类药物不同,硫喷妥钠仅在直接激活CD3/CD28受体时降低ras和JNK活性。相反,在PMA/离子霉素刺激下,硫喷妥钠独立于小G蛋白ras和MAP激酶阻断AP-1依赖的基因表达,从而提示存在一种额外的、未知的AP-1调节机制。总之,我们的结果有助于解释巴比妥类药物治疗患者临床表现出的免疫抑制现象,并支持人T细胞中蛋白激酶C和钙对AP-1进行不依赖MAP激酶调节的观点。